Pfizer, Haleon

Pfizer to sell $3 billion stake in Sensodyne maker Haleon
Pfizer will sell shares worth 2.50 billion pounds ($3.05 billion) in Haleon, lowering its stake in the British consumer healthcare company to about 7.3% from 15%, its bookrunner JPMorgan said on Wednesday.
Pfizer Sells 700 Million Haleon Shares for $3.05 Billion
The sale decreases Pfizer’s shareholding in the consumer-healthcare business to 7.3% of its issued share capital, down from 15%.
Pfizer to sell 700M ordinary shares of Haleon
Pfizer (PFE) announces that it intends to sell approximately 700M ordinary shares in Haleon plc (HLN), representing approximately 7.7% of
Pfizer Has Sold 700M Haleon Shares
Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing opportunities, strengthen advisor-client relationships and build investor experiences. Learn More. Back To Top
Why Pfizer sold its $3 billion stake in Haleon
Pfizer’s decision to offload $3.05 billion worth of shares in Haleon is a strategic move driven by shifting priorities in a volatile pharmaceutical market. The transaction, involving 700 million shares priced at 357 pence each,
Pfizer to cut Haleon stake in 700M share sale
Pfizer (NYSE:PFE) announced Tuesday it plans to sell roughly 700M ordinary shares in Haleon (NYSE:HLN) to lower its stake in the British consumer healthcare giant from about 15.0% to 7.3%, implying a divestment of approximately 7.
FiercePharma3h
In PAHO-backed access initiative, Argentina's Sinergium Biotech to locally produce Pfizer's Prevnar 20
Pfizer’s latest-generation pneumococcal conjugate vaccine is in line to reach more people in Latin America and the Caribbean ...
Pfizer appeals denial of $75 million claim in SEC case against Cohen hedge fund
Pfizer on Tuesday appealed a federal judge's refusal to award the drugmaker $75.2 million from a more than decade-old insider ...
Pfizer Eyes $20 Billion Revenue From Acquisitions Amid Patent Cliff Challenges
While presenting at the JP Morgan Healthcare Conference, Pfizer Inc. (NYSE:PFE) Albert Bourla, Chairman and CEO, said, “I ...
STAT2d
Defiant, Pfizer CEO talks about Trump, obesity drugs, and the ‘Pfizer machine’
At the JPM conference, Pfizer CEO Albert Bourla projected optimism, saying the market was overlooking the pharma company's ...
Pfizer going 'all in' on obesity drug development, CEO Bourla says
U.S. drugmaker Pfizer is going "all in" to develop its experimental obesity drug and has been recruiting more experts in that ...
BioSpace2d
Pfizer Cautiously Optimistic on Obesity Pill as Kailera Challenges Lilly’s Zepbound With Strong Phase II Data
Obesity continues to grab attention at the J.P. Morgan Healthcare Conference in San Francisco, with both Pfizer and Kailera ...
Pfizer’s Growth Potential and Strategic Focus Justify Buy Rating Amid Healthcare Policy Shifts
Analyst Evan Seigerman from BMO Capital maintained a Buy rating on Pfizer (PFE – Research Report) and keeping the price target at $36.00.Stay ...
What To Expect From PFE Stock In 2025?
In this note, while we briefly touch upon Pfizer’s performance in 2024, we focus on the impact on PFE stock and how 2025 ...